- Ticker
- ABIO
- Price
- 2.05
- Stock movement down
- -0.06 (-2.84%)
- Company name
- ARCA Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Marktkapitalisierung
- 29.54M
- Ent-Wert
- -12.16M
- Preis/Umsatz
- -
- Preis/Buch
- 0.69
- Div-Ertrag
- -
- Div Wachstum
- -
- Wachstumsjahre
- -
- FCF-Ausschüttung
- -
- Nachlaufendes KGV
- -
- Forward P/E
- -
- PEG
- -
- EPS-Wachstum
- -
- 1 Jahr Rückkehr
- -13.87%
- 3-Jahres-Rendite
- -7.62%
- 5-Jahres-Rendite
- -28.70%
- 10-Jahres-Rendite
- -40.13%
Zuletzt aktualisiert: 2023-03-22
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
28. Oktober 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2. August 2022
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABIO keine Dividenden ausschüttet
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2. August 2022
iO Charts is a Seeking Alpha partner
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Click here to learn more about ABIO stock.
3. Mai 2022
iO Charts is a Seeking Alpha partner
BEWERTUNG
Bewertungskennzahlen
Loading...
Daten zu den Bewertungsverhältnissen
| Nachlaufendes KGV | - |
| Preis zu OCF | - |
| Preis zu FCF | - |
| Preis zu EBITDA | - |
| EV zu EBITDA | - |
Bewertung (Umsatz/Buchwert)
Loading...
Bewertungsdaten (Umsatz/Buchwert)
| Preis zu Umsatz | - |
| Preis zum Buchen | 0.69 |
| EV zu Verkäufen | - |
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2. Mai 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
18. April 2022
iO Charts is a Seeking Alpha partner
FINANZEN
Pro Aktie
Loading...
Angaben pro Aktie
| Aktuelle Anzahl der Aktien | 14.41M |
| EPS (TTM) | -1.00 |
| FCF pro Aktie (TTM) | -1.00 |
Gewinn- und Verlustrechnung
Loading...
Daten der Gewinn- und Verlustrechnung
| Umsatz (TTM) | 0.00 |
| Bruttogewinn (TTM) | 0.00 |
| Betriebsergebnis (TTM) | -14.73M |
| Reingewinn (TTM) | -14.43M |
| EPS (TTM) | -1.00 |
| EPS (1 Jahr vorwärts) | - |
Margen
Loading...
Daten zu den Margen
| Bruttomarge (TTM) | - |
| Operative Marge (TTM) | - |
| Gewinnspanne (TTM) | - |
Bilanz
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Bilanzdaten
| Bargeld | 43.94M |
| Nettoforderungen | 0.00 |
| Umlaufvermögen insgesamt | 44.55M |
| Goodwill | 0.00 |
| Immaterielle Vermögenswerte | 0.00 |
| Sachanlagen und Ausrüstung | 0.00 |
| Gesamtvermögen | 44.97M |
| Verbindlichkeiten aus Lieferungen und Leistungen | 593.00K |
| Kurz-/kurzfristige langfristige Schulden | 301.00K |
| Kurzfristige Verbindlichkeiten insgesamt | 1.94M |
| Verbindlichkeiten insgesamt | 2.24M |
| Aktionärseigenkapital | 42.73M |
| Netto-Sachanlagen | 42.73M |
Cashflow
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Cashflow-Daten
| Operativer Cashflow (TTM) | -14.37M |
| Investitionsausgaben (TTM) | 9.00K |
| Freier Cashflow (TTM) | -14.37M |
| Ausgeschüttete Dividenden (TTM) | 0.00 |
Finanzielle Erträge
Loading...
Bitte erstellen Sie ein kostenloses Konto oder melden Sie sich an, um auf diese Tabelle zuzugreifen.
Daten zu Finanzerträgen
| Eigenkapitalrendite | -33.77% |
| Kapitalrendite | -32.09% |
| Rentabilität des investierten Kapitals | -33.77% |
| Cash Return on Invested Capital | -33.64% |
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
31. März 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
14. März 2022
iO Charts is a Seeking Alpha partner
BESTANDSINFORMATIONEN
Aktienchart
Loading...
Daten zum Aktienkurs
| Öffnen Sie | 2.10 |
| Tageshöchststand | 2.10 |
| Tägliches Tief | 2.05 |
| Tägliches Volumen | 15K |
| Allzeithoch | 5726700.00 |
| 1-Jahres-Analystenschätzung | 7.00 |
| Beta | 1.64 |
| EPS (TTM) | -1.00 |
| Dividende je Aktie | - |
| Ex-Div-Datum | 1 May 2006 |
| Nächstes Ergebnisdatum | 1 May 2023 |
Nachteiliges Potenzial
Loading...
Nachteilige potenzielle Daten
| ABIO | S&P500 | |
| Aktueller Preisrückgang vom Allzeithoch | -100.00% | -17.92% |
| Höchster Preisrückgang | -100.00% | -56.47% |
| Datum des höchsten Rückgangs | 22 Mar 2023 | 9 Mar 2009 |
| Durchschnittlicher Rückgang vom Höchststand | -93.88% | -11.51% |
| Durchschnittliche Zeit bis zum neuen Höchststand | 280 days | 13 days |
| Maximale Zeit bis zum neuen Höchststand | 5809 days | 1805 days |
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2. Dezember 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2. November 2021
iO Charts is a Seeking Alpha partner
UNTERNEHMENSDATEN
Marketcap
29.54M
Kategorie Marktkapitalisierung
Small-cap
Beschreibung
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Mitarbeiter
17
Website
Investor Relations
-
SEC-Anmeldungen
CEO
Michael R. Bristow
Land
USA
Stadt
Westminster
Art des Bestands
Common stock
CCC-Status
-
Häufigkeit der Ausschüttung
-
VERANSTALTUNGEN UND PRÄSENTATIONEN
VeranstaltungenPräsentationen
Loading...
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
28. Oktober 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
16. September 2021
iO Charts is a Seeking Alpha partner
DAS GESCHÄFT VERSTEHEN
Loading...
The following slide deck was published by ARCA biopharma, Inc.
23. August 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
9. August 2021
iO Charts is a Seeking Alpha partner
UNTERNEHMENSNACHRICHTEN
Alle NachrichtenPresseveröffentlichungen
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE...
24. Februar 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although...
3. Februar 2023
WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to ...
19. Dezember 2022
Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...
14. November 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE...
28. Oktober 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIR...
2. August 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
18. Juli 2022
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-We...
21. Juni 2022
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 20...
5. Mai 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE...
2. Mai 2022
Nächste Seite
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
4. August 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
13. Juli 2021
iO Charts is a Seeking Alpha partner